On Tuesday, Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR)’s shares declined -0.67% to $4.42. The market capitalization of Petroleo Brasileiro SA Petrobras (ADR)(NYSE:PBR) is $26.23 billion with the total traded volume of the company is 12.89 million. Turning to market valuation, the Price-to-Sales ratio is 0.30 and the Price-to-Book ratio is finally 0.95. The dividend yield amounts to 10.86 percent and the beta ratio has a value of 2.13.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Merck & Co., Inc. (NYSE:MRK)’s shares gained 0.95% to $53.34.
Merck (MRK), known as MSD outside the United States and Canada, declared that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV∆G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).
According to the WHO, the EUAL process is designed to expedite the availability of vaccines needed for public health emergencies such as another outbreak of Ebola. The procedure is intended to assist United Nations’ procurement agencies and Member States on the acceptability of using a vaccine candidate in an emergency-use setting. EUAL designation is not prequalification by WHO, but rather is a special procedure implemented when there is an outbreak of a disease with high rates of morbidity and/or mortality and a lack of treatment and/or prevention options. In such instances, WHO may recommend making a vaccine accessible for a limited time, while further clinical trial data are being gathered for formal regulatory agency review by a national regulatory authority.
“This application to the WHO is an important step toward enabling V920 to be used if a public health emergency of international concern were to be declared for the Ebola Zaire species preceding to licensure of the vaccine candidate,” said Paula Annunziato, M.D., vice president for clinical research, Merck Research Laboratories.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. I
Tyson Foods, Inc. (NYSE:TSN)‘s shares surged 0.69% to $53.90. Tyson Foods, Inc. (NYSE:TSN) is now worth about $19.64 billion. The share price has made a 2.57% gain in the past 5 days and has gained 34.45% since 2015 kicked off. Analysts are forecasting EPS growth of 2.95% for next fiscal year and 12.36% growth in the next 5 years. The stock trades with a beta of 0.44. The stock price is above by 24.51% as contrast to the average price over the last 200 days. The company has 9.50% gross margins.
Tyson Foods, Inc., together with its auxiliaries, operates as a food company worldwide. It operates through four segments: Chicken, Beef, Pork, and Prepared Foods. The company raises and processes chickens into fresh, frozen, and value-added chicken products; processes live fed cattle and live market hogs; and fabricates dressed beef and pork carcasses into primal and sub-primal meat cuts, in addition to case ready beef and pork, and fully-cooked meats.